**Supplementary material**

**Supplementary Table 1 Association between total volume of MSU crystal depositions and patient-/physician-reported assessments on day 1**

| **Parameter** | **n** | **Total volume of MSU crystal depositions (cm3)(N=152)** |
| --- | --- | --- |
| Patient-reported assessments |
| *Global impression of disease activity score\** |
| Spearman correlation coefficient, r† | 152 | 0.31 |
| p Value† | 0.0001 |
| *Impression of disease control score*‡ |
| Spearman correlation coefficient, r† | 152 | –0.25 |
| p Value† | 0.002 |
| Assessment of pain score§ |
| Spearman correlation coefficient, r† | 152 | 0.08 |
| p Value† | 0.34 |
| Physician-reported assessments |  |
| *Global impression of disease activity score*|| |
| Spearman correlation coefficient, r† | 152 | 0.21 |
| p Value† | 0.01 |
| *Impression of disease control score*¶ |
| Spearman correlation coefficient, r† | 152 | –0.33 |
| p Value† | <0.0001 |
| \*Score ranges from 0 (very well) to 10 (very poor); lower scores indicate lower disease activity.†Estimates are from Spearman correlation.‡Score ranges from 0 (not at all controlled) to 10 (fully controlled); higher scores indicate disease is under control.§Score ranges from 0 (no pain) to 10 (severe pain); lower scores indicate less pain. |
| ||Score ranges from 0 (none) to 10 (extremely active); lower scores indicate lower disease activity.¶Score ranges from 0 (not at all controlled) to 10 (fully controlled); higher scores indicate disease is under control.MSU, monosodium urate. |

**Supplementary Table 2 Association between presence of joint erosions and baseline characteristics**

|  |  |  |
| --- | --- | --- |
| **Parameter** | **n** | **Joint erosion** |
| **Presence(n=110)** | **Absence(n=42)** |
| *Age* |
|  p Value† | 152 | 0.18 |
| *Age categories (n [%])* |
| <65 years | 100 | 70 (70.0) | 30 (30.0) |
| ≥65 years | 52 | 40 (76.9) | 12 (23.1) |
|  p Value‡ | 0.37 |
| *Sex (n [%])* |
|  Male | 140 | 105 (75.0) | 35 (25.0) |
|  Female | 12 | 5 (41.7) | 7 (58.3) |
|  p Value§ | 0.02 |
| *Race categories (n [%])* |
| White | 98 | 68 (69.4) | 30 (30.6) |
| Non-white | 54 | 42 (77.8) | 12 (22.2) |
| p Value‡ | 0.27 |
| *Baseline allopurinol dose category (n [%])* |
| 300 mg | 124 | 82 (66.1) | 42 (33.9) |
| >300 mg | 28 | 28 (100.0) | 0 (0.0) |
| p Value‡ | 0.0003 |
| *Duration on allopurinol (years)* |
| p Value† | 152 | 0.07 |
| *Tophus status (n [%])* |
| Presence | 48 | 40 (83.3) | 8 (16.7) |
| Absence | 104 | 70 (67.3) | 34 (32.7) |
| p Value‡ | 0.04 |
| *Number of tophi locations (n [%])* |
|  None | 104 | 70 (67.3) | 34 (32.7) |
|  1 location only | 21 | 15 (71.4) | 6 (28.6) |
|  2 locations | 9 | 8 (88.9) | 1 (11.1) |
|  >2 locations | 18 | 17 (94.4) | 1 (5.6) |
|  p Value§ | 0.06 |
| *Duration of gout since diagnosis (years)* |
|  p Value† | 152 | 0.52 |
| *Gout flares in the past 12 months (n [%])* |
|  None | 70 | 51 (72.9) | 19 (27.1) |
|  ≥1 | 82 | 59 (72.0) | 23 (28.0) |
|  p Value‡ | 0.90 |
| *Gout flares in the past 3 months (n [%])* |
|  None | 110 | 80 (72.7) | 30 (27.3) |
|  ≥1 | 42 | 30 (71.4) | 12 (28.6) |
|  p Value‡ | 0.87 |
| *Medical history of kidney stones (n [%])* |
|  Yes | 22 | 13 (59.1) | 9 (40.9) |
|  No | 130 | 97 (74.6) | 33 (25.4) |
|  p Value‡ | 0.13 |
| *BMI (kg/m²)* |
|  p Value† | 152 | 0.16 |
| *Day 1 sUA (n [%])* |
|  <6.0 mg/dL | 77 | 53 (68.8) | 24 (31.2) |
|  ≥6.0 mg/dL | 75 | 57 (76.0) | 18 (24.0) |
|  p Value‡ | 0.32 |
| *Renal function groupǁ (n [%])* |
|  <90 mL/min | 115 | 85 (73.9) | 30 (26.1) |
|  ≥90 mL/min | 35 | 23 (65.7) | 12 (34.3) |
|  p Value‡ | 0.34 |
|  <60 mL/min | 36 | 27 (75.0) | 9 (25.0) |
|  ≥60 mL/min | 114 | 81 (71.1) | 33 (28.9) |
|  p Value‡ | 0.65 |
| *C-reactive protein (mg/L)* |
|  p Value† | 149 | 0.49 |
| Percentages are based on the number of patients within each category.†p Value is obtained using logistic regression.‡p Value is obtained using Pearson’s Chi-square test.§p Value is obtained using Fisher’s exact testǁRenal function group is the estimated creatinine clearance based on the Cockcroft-Gault method.BMI, body mass index; sUA, serum urate. |